James Doherty - Acumen Pharmaceuticals President Officer
| ABOS Stock | USD 3.49 0.01 0.29% |
President
James Doherty is President Officer of Acumen Pharmaceuticals
| Age | 56 |
| Address | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Phone | 434 297 1000 |
| Web | https://acumenpharm.com |
Acumen Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1508) % which means that it has lost $0.1508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2298) %, meaning that it created substantial loss on money invested by shareholders. Acumen Pharmaceuticals' management efficiency ratios could be used to measure how well Acumen Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.22 in 2024. At this time, Acumen Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 66.7 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 145.8 K in 2024.Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.15 |
Acumen Pharmaceuticals Leadership Team
Elected by the shareholders, the Acumen Pharmaceuticals' board of directors comprises two types of representatives: Acumen Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acumen. The board's role is to monitor Acumen Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acumen Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acumen Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Bockenstette, Ex HR | ||
| JD Esq, Chief Secretary | ||
| Siew MS, Assistant Operations | ||
| Grant Krafft, CoFounder | ||
| Robyn MA, Manager Communications | ||
| Daniel MBA, President CEO | ||
| James Doherty, President Officer | ||
| Caleb Finch, CoFounder | ||
| Kelly Carranza, Finance President | ||
| Janice Hitchcock, VP Affairs | ||
| William Klein, CoFounder | ||
| Russell MS, Chief Officer | ||
| Matt Zuga, CFO Officer | ||
| Eric MD, Chief Officer | ||
| Liean MS, VP CMC | ||
| Alex MBA, VP Relations |
Acumen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acumen Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (2.8 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 9.12 % | ||||
| Shares Owned By Institutions | 72.73 % | ||||
| Number Of Shares Shorted | 1.05 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) |
Pair Trading with Acumen Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acumen Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acumen Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Acumen Stock
| 0.7 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Moving against Acumen Stock
| 0.46 | RGC | Regencell Bioscience | PairCorr |
The ability to find closely correlated positions to Acumen Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acumen Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acumen Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acumen Pharmaceuticals to buy it.
The correlation of Acumen Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acumen Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acumen Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acumen Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Acumen Stock analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 0.033 | Return On Assets (0.15) | Return On Equity (0.23) |
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acumen Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.